Gemini Therapeutics (GMTX) Stock Price, News & Analysis

Company Overview

Gemini Therapeutics, Inc., a clinical stage precision medicine company, engages in developing various therapeutic compounds for treating genetically defined age-related macular degeneration (AMD). Its lead candidate is GEM103, a recombinant form of the human complement factor H protein to treat dry AMD patients. The company also develops GEM307 for treatment of systemic diseases. Gemini Therapeutics, Inc. was founded in 2015 and is headquartered in Cambridge, Massachusetts.

Key Stats

• Today's Range: $52.06 to $54.01
• 50-Day Range: $51.02 to $60.52
• 52-Week Range: $1.16 to $14.10
• Volume: 1.08 million shs
• Average Volume: 189,291 shs
• Market Capitalization: $2.26 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

GMTX Stock Analysis - Frequently Asked Questions

How have GMTX shares performed this year?

Gemini Therapeutics' stock was trading at $63.40 at the beginning of 2025. Since then, GMTX shares have decreased by 17.6% and is now trading at $52.24.
View the best growth stocks for 2025 here.

How were Gemini Therapeutics' earnings last quarter?

Gemini Therapeutics, Inc. (NASDAQ:GMTX) issued its earnings results on Monday, November, 15th. The company reported ($0.43) EPS for the quarter, beating the consensus estimate of ($0.47) by $0.04.

How do I buy shares of Gemini Therapeutics?

Shares of GMTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Gemini Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Gemini Therapeutics investors own include Alphabet (GOOG), Meta Platforms (META), NVIDIA (NVDA), Zoom Video Communications (ZM), Activision Blizzard (ATVI), Fiverr International (FVRR) and Shopify (SHOP).

Company Calendar

• Last Earnings: 11/15/2021
• Today: 3/24/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:GMTX
• CIK: 1816736
• Web: www.geminitherapeutics.com
• Phone: 415-877-4887
• Fax: N/A
• Employees: 30
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): ($1.00)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-71,870,000.00
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -38.78%
• Return on Assets: -35.88%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 71.49
• Quick Ratio: 71.49

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $2.89 per share
• Price / Book: 18.08

Miscellaneous

• Outstanding Shares: 43,328,000
• Free Float: 37,739,000
• Market Cap: $2.26 billion
• Optionable: Not Optionable
• Beta: -0.12